PROGRAM Time Converter

GMT+09:00 (Korea, Japan)

11:50-12:00

Opening

Jinsil Seong (President)

12:00-13:00

SESSION 1: RISK FACTORS, SURVEILLANCE AND PREVENTION

Namiki Izumi (Musashino Red Cross Hospital, Tokyo)

12:00-12:15

Risk Factors and prevention (Primary, Secondary, Tertiary)

Junqi Niu (Jilin Univ., Jilin)

12:15-12:30

Biomarkers for HCC and CC

Kwang-Hyub Han (NECA, Seoul)

12:30-12:45

Current Recommendation for Surveillance

Young Suk Lim (Univ. of Ulsan, Seoul)

12:45-13:00

Discussion

Namiki Izumi (Musashino Red Cross Hospital, Tokyo), Kwang-Hyub Han (NECA, Seoul)

13:00-13:10

Break

13:10-14:10

SESSION 2: DIAGNOSIS AND STAGING FOR HCC AND CC

Hirohisa Yano (Kurume Univ., Kurume)

13:10-13:25

Pathological Diagnosis for HCC and CC: New WHO Classification

Irene Ng (The Univ. of Hong Kong , Hong Kong)

13:25-13:40

Imaging for HCC and CC: Diagnosis and Response Evaluation

Choon Hua Thng (National Cancer Centre Singapore, Singapore)

13:40-13:55

Treatment algorithm of Current Guidelines for HCC

Ann-Lii Cheng (National Taiwan Univ., Taipei)

13:55-14:10

Case Discussion

Hirohisa Yano (Kurume Univ., Kurume), Irene Ng (The Univ. of Hong Kong, Hong Kong)

14:10-14:20

Break

14:20-15:35

SESSION 3: LIVER-DIRECTED THERAPY

Pierce Chow (National Cancer Centre Singapore, Singapore)

14:20-14:35

Surgical Resection: Update for HCC and CC

Kyung-Suk Suh (Seoul National Univ., Seoul)

14:35-14:50

Liver Transplantation: Selection Criteria & Outcomes

Albert Chan (The Univ. of Hong Kong, Hong Kong)

14:50-15:05

Transarterial Chemoembolization (TACE)

Jin Wook Chung (Seoul National Univ., Seoul)

15:05-15:20

Radiation Therapy

Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)

15:20-15:35

Case Discussion

Pierce Chow (National Cancer Centre Singapore, Singapore), Jason Chia-Hsien Cheng (National Taiwan Univ., Taipei)

15:35-15:50

Break

15:50-16:50

SESSION 4: SYSTEMIC TREATMENT FOR HCC AND CC

Chiun Hsu (National Taiwan Univ., Taipei)

15:50-16:05

Systemic Therapy for HCC

Han Chong Toh (National Cancer Centre Singapore, Singapore)

16:05-16:20

Systemic Therapy for CC

Stephen Chan (The Chinese Univ. of Hong Kong, Hong Kong)

16:20-16:35

Clinical Trial Design and Analysis: Lessons from Trials of Targeted Therapy and Immunotherapy for HCC

Masafumi Ikeda (National Cancer Center Hospital East, Tokyo)

16:35-16:50

Discussion

Chiun Hsu (National Taiwan Univ., Taipei), Han Chong Toh (National Cancer Centre Singapore, Singapore)

16:50-17:00

Closing Remarks

Irene Ng and Chiun Hsu (Education Chairs)

17:00-17:30

APPLE Academy Satellite Symposium